One-year hemodynamic and clinical outcomes in self-expanding valves: Comparison of ACURATE neo2 versus ACURATE neo
This study compared one-year all-cause mortality and hemodynamic outcomes after TAVR between ACURATE neo2 and ACURATE neo implantation. One-year all-cause mortality rate and significant improvement in the mean APG after TAVR for ACURATE neo2 were similar to those of ACURATE neo. ACURATE neo2 revealed the subsequent improvement of significant PVL for one year, which might result in better long-term clinical outcomes than ACURATE neo.
Authors
- Mikko Jalanko (ORCID: https://orcid.org/0000-0001-5409-3300)
- Mika Laine (ORCID: https://orcid.org/0000-0002-6906-8877)
- Hirokazu Miyashita (ORCID: https://orcid.org/0000-0003-1562-9437)
- Juho Viikilä (ORCID: https://orcid.org/0000-0003-1227-8440)
- Noriaki Moriyama (ORCID: https://orcid.org/0000-0002-8570-5901)
- Tiina Vainikka
- Sebastian Dahlbacka (ORCID: https://orcid.org/0000-0003-3336-3118)
- Tommi Vähäsilta
- Yoichi Sugiyama (ORCID: https://orcid.org/0000-0001-8363-9632)
Institutions
- Helsinki University Hospital (FI)
- Shonan Kamakura General Hospital (JP)
Publication Details
- Journal
- Cardiovascular revascularization medicine
- Published
- 2024-12-22
- DOI
- https://doi.org/10.1016/j.carrev.2024.12.008
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00